IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial

RegulatoryapprovedPositive

AI Analysis

Summary

Ionis Pharmaceuticals received FDA approval for a neurology drug, driving after-hours gains. The stock movement was tempered by Ultragenyx's failed trial announcement on the same day.

Outcome Details

FDA approval for neurology drug

Importance:7/10

Sentiment:

0.70

FDA approvalneurologyafter-hours tradingIONSRARE

Related Companies

$IONS $RARE

Read the original article

Published by yahoo_finance on September 3, 2026 9:19 PM

Read Original